Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
Frazier Life Sciences Public Fund, L.P. - 18 Dec 2025 SCHEDULE 13G Report for VOR BIOPHARMA INC. Common Stock, $0.0001 par value per share (VOR)
- Filing manager
- Frazier Life Sciences Public Fund, L.P.
- Reporting owner
- Frazier Life Sciences Public Fund, L.P.
- Beneficially owned shares
- 2,258,001 shares
- Large-stake signal
-
Ownership
5.8%Beneficial ownership of this reported class.
Shares
2,258,001 sharesShares beneficially owned as disclosed.
Event date
18 Dec 2025Date tied to the ownership event or amendment.
Accepted by SEC
19 Dec 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 5.8%
- Symbol
- VOR
- Shares outstanding
- 38,931,052 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 19 Dec 2025, 16:40:21 UTC
- Event date
- 18 Dec 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
Frazier Life Sciences Public Fund, L.P. disclosed 5.8% ownership in VOR BIOPHARMA INC. Common Stock, $0.0001 par value per share (VOR) on 18 Dec 2025.
Key facts
- Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G for VOR BIOPHARMA INC. Common Stock, $0.0001 par value per share (VOR).
- Disclosed ownership: 5.8%.
- Date of event: 18 Dec 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 19 Dec 2025, 16:40.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (9)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 5.8% | 2,258,001 | 0 | 2,258,001 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. | |
| FHMLSP, L.P. | 5.8% | 2,258,001 | 0 | 2,258,001 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. | |
| FHMLSP, L.L.C. | 5.8% | 2,258,001 | 0 | 2,258,001 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C. | |
| Frazier Life Sciences XI, L.P. | 0.1% | 21,114 | 0 | 21,114 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. | |
| FHMLS XI, L.P. | 0.1% | 21,114 | 0 | 21,114 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. | |
| FHMLS XI, L.L.C. | 0.1% | 21,114 | 0 | 21,114 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C. | |
| Frazier Life Sciences XII, L.P. | 0.7% | 264,824 | 0 | 264,824 | /s/ Gordon Empey | By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P. | |
| FHMLS XII, L.P. | 0.7% | 264,824 | 0 | 264,824 | /s/ Gordon Empey | By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P. | |
| FHMLS XII, L.L.C. | 0.7% | 264,824 | 0 | 264,824 | /s/ Gordon Empey | By Gordon Empey, General Counsel of FHMLS XII, L.L.C. |
CIK / CUSIP context first